Perospirone (Lullan) is an aberant
antipsychotic of the azapirone family. It was alien in Japan by
Dainippon Sumitomo Pharma in 2001 for the analysis of schizophrenia and astute
cases of bipolar mania.
Its primary uses are in the analysis of
schizophrenia and bipolar mania.
In a analytic balloon that compared it to
haloperidol in the analysis of schizophrenia it was begin to aftermath
decidedly above all-embracing evidence control. In addition analytic balloon
perospirone was compared with mosapramine and produced a agnate abridgement in
absolute PANSS score, except with account to the blunted affect allotment of
the PANSS abrogating score, in which perospirone produced a decidedly greater
improvement. In an open-label analytic balloon comparing aripiprazole with
perospirone there was no cogent aberration amid the two treatments apparent in
agreement of both ability and tolerability. In 2009 a analytic balloon begin
that perospirone produced a agnate abridgement of PANSS account than
risperidone and the extrapyramidal ancillary furnishings was agnate in both
abundance and severity amid groups.
A meta-analysis appear in 2013 begin that
it is statistically decidedly beneath active than added second-generation
antipsychotics.
No comments:
Post a Comment